Zhou Yun took the bid. Didn't speak. Raise your hand and look at your watch. The stopwatch hands jump. This put tremendous pressure on the eight representatives of pharmaceutical companies. John Spruen roughly loosened his tie.

Brian Bernie took a deep breath.

Aldrich Alvin crossed his fingers and propped his chin on,......。

In the room, the air seemed to freeze. Everyone was silent.

Zhou Yun looked at his watch, and the seconds hand jumped. When the second hand jumped the dial 12, at this time, Zhou Yun said, "It's 10 o'clock." Deadline for bidding. Now I open the bid. and announce the winner. ”

Zhou Yun picked up a tender book, opened the cover page, looked at it, and said, "The patent licensing fee given by Merck is $4.77 billion. The patent share ratio is 37.6%. ”

At this time, Merck representative Brian Burke looked around at the other seven competitors, trying to see their expressions, but all seven were expressionless. He was a little apprehensive. These two figures were calculated by dozens of senior actuaries working overtime for three days.

According to data published by the United Nations, there are 39.5 million people living with AIDS worldwide. Add in the number of people who hide that they have AIDS, and the number is assumed to be 50 million. Of these, Africa accounts for 70 per cent. Many African tribes are backward and ignorant. They don't even know about AIDS, they don't care about AIDS, and they can't afford $1 to buy fragrance preparations to cure AIDS.

So, in the end, there are still about 20 million people with AIDS who are looking forward to the launch of the fragrance preparation.

The production cost of a tube of fragrance preparation is $12.6,...... The cost of curing an AIDS patient is about $14,000.

In this cost-to-profit model, PR costs, clinical trial costs, are also added. The cost of R&D in the second stage. The cost of litigation against generic drugs, and the infringement of patented drugs by generic drugs. ...... Wait a minute. In the end, it was calculated and a bidding plan was come up. Probably 7 of its pharmaceutical companies are like this.

Zhou Yun picked up the second bid, opened the cover, looked at it, and read, "The patent licensing fee given by Novo Nordisk is 8.16 billion US dollars, and the patent sharing ratio is 31.6%. "Compared with Merck's bid competition strategy, Novo Nordisk's bid competition strategy is to significantly increase the patent licensing fee and reduce the patent sharing ratio.

Novo Nordisk's think tank team reasoned that Zhou Yun might be inclined to higher royalties. As it turned out, they guessed right. However, there is no prize. Afterwards, Novo Nordisk's think tank team reviewed it once. Zhou Yun only considers short-term interests, not long-term interests. It is better to lose more long-term benefits than short-term benefits. They certainly don't know that Zhou Yun is going to take more money to buy shares of Apple and Tencent.

At this time, everyone, including Dai Xinliang, was observing Zhou Yun's expression, trying to judge from Zhou Yun's expression whether he was inclined to a higher patent licensing fee or a higher patent sharing ratio.

Zhou Yun's face was expressionless. You can't guess what Zhou Yun thinks. Zhou Yun already had the answer in his heart.

Novo Nordisk spends $4 billion a year on research and development. The annual profit is about 30 billion Danish kroner, which is about 4.5 billion US dollars in US dollars. Compared to Pfizer, Novo, Merck, these big giants, Novo Nordisk is a small giant. It's just that small giants also have dreams. The $8.16 billion patent grant fee can be paid, as long as the patent for the fragrance compound is obtained. There are a large number of financial institutions that are willing to borrow. A blockbuster drug can make a world-class pharmaceutical giant. For example, Viagra is to Pfizer. Gleevec to Novartis.

The validity period of a drug patent is 20 years, about 3 years after deducting the time it takes between the drug compound and the approval of the drug for marketing. Defragrance preparations can be sold for at least 16 years. The money earned back is 4,5 times.

The key is the patent share ratio.

Novo Nordisk's representatives were expressionless. No one could have guessed what he was thinking.

Zhou Yun picked up the third bid, opened the cover, and read, "The patent grant fee given by AbbVie is $5.46 billion. The patent share ratio is 37.5%. "Compared with Merck, AbbVie gave $690 million more than Merck & Co., Ltd. The patent share is only 0.1% lower. Basically, the first one to come out was Merck.

Merck representative Brian Bernie let out a cry of grief and frustration on his face. Cover your face with your hands. I almost cried.

AbbVie, who kicked Merck out of the game. Aldrich Alwyn's face was not easy either. Until the results of the bidding are out, no one present will be relaxed.

Zhou Yun picked up the fourth bid, opened the cover, and read, "The patent licensing fee given by AstraZeneca is 7.36 billion US dollars. The patent share ratio is 33.6%. ”

Four tenders have been made public.

Merck was kicked out first. There is no doubt about it.

Novo Nordisk, AbbVie, AstraZeneca, in the case of 4 bids that have not been disclosed, at present, who has more advantages, in fact, everyone does not know.

One thing is very clear to everyone. The key to winning is whether Zhou Yun prefers a higher patent licensing fee or a higher patent share ratio.

Zhou Yun picked up the fifth bid, opened the cover, looked at it, and read, "The patent licensing fee given by Howfman Roche is 8.87 billion US dollars. The patent share ratio is 33.1%. ”

Howfmai Roche is a frequent visitor to the top three pharmaceutical companies in the world. The annual R&D cost is more than $9 billion. Prescription drug sales are more than $40 billion.

$8.87 billion can be out. No problem. The key is the patent share ratio. What makes the 8 pharmaceutical giants the most painful and numbing is also this patent sharing ratio.

This patent share ratio is more ruthless than the Qualcomm tax. Suck their blood. When will it be someone else's turn to suck their blood.

Apple sells a mobile phone and pays Qualcomm about $40 in royalties.

However, according to this percentage, they sell every tube of the fragrance preparation, for example, a tube of the fragrance preparation sells for $10,000. It will be distributed to Qingxiang Biopharmaceutical Co., Ltd., about $2,500 in patent shares. If, they make $10 billion a year from fragrance compounds. It will be divided into more than 3 billion US dollars to Qingxiangguo Biopharmaceutical Company (China).

Zhou Yun picked up the fifth bid, opened the cover page, and read, "The patent licensing fee given by Novartis is 10.12 billion US dollars. The patent share ratio is 28.6%. ”

Novartis is a world-class pharmaceutical giant and a pharmaceutical giant.

Market capitalization $180 billion. The company has developed a drug for chronic leukemia called imatinib mesylate tablets, which in China is called Gleevec. At its peak, annual sales of the drug exceeded $5 billion. Novartis' annual R&D costs also exceed $9 billion.

$10.12 billion is only a little higher than the annual R&D cost. Can be out. What also makes Novartis numb is that the patent share ratio. Novartis' bid competition strategy is to increase patent licensing fees and reduce the patent share ratio.

......

Finally, Pfizer also adopted this bidding strategy.

Zhou Yun picked up the eighth bidding book, opened the cover, glanced at it, and read, "The patent licensing fee given by Pfizer is 12.52 billion US dollars. The patent share ratio is 24.6%. ”

Pfizer's bidding strategy has gone to an extreme. The sky-high patent licensing fee has reduced the patent share ratio on this basis.

Compared with Merck, Pfizer's patent licensing fee is $7.75 billion higher than Merck's. However, the share of patents is 13% less. It's a clever strategy. But also very adventurous.

-----

Book friends. It's okay to watch. Favorites. Vote for your recommendation. Thank you.